Adult HTN Initially 60 mg once daily. May be increased to 120 mg once daily if BP is not adequately controlled. Severe renal impairment (CrCl <30 mL/min) Initially 30 mg once daily. Max: 60 mg. Intravascular vol-depleted patients Initially 30 mg once daily.
Hypersensitivity to sunset yellow FCF. Closely monitor patients w/ intravascular vol- or salt-depletion. Increased risk for severe HTN in patients w/ uni- or bi-lateral renal artery stenosis. Patients w/ aortic or mitral valve stenosis, obstructive or hypertrophic cardiac myopathy like other vasodilators. Not recommended for patients w/ primary aldosteronism. Renal impairment; moderate to severe hepatic impairment. May affect the ability to drive & operate machinery. Ped patients ≤18 yr. Elderly >70 yr.
May increase serum K w/ K-sparing diuretics (eg, spironolactone), K supplements & salt alternatives containing K, & drugs that may increase serum K (heparin). Increased BP-lowering effects w/ other antihypertensives, including diuretics. Reversibly increased in serum levels & toxicities of lithium. Reduced BP-lowering effects w/ NSAIDs (eg, aspirin, COX-2 inhibitors). Increased risks of hypotension, syncope, hyperkalemia & changes in renal failure (including acute failure) w/ angiotensin II receptor blocker, ACE inhibitors or aliskiren. Increased AUC w/ ketoconazole, rifampicin or other OATP1B1 transporter inhibitors.
Sign Out
